<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02337322</url>
  </required_header>
  <id_info>
    <org_study_id>Advanz-4</org_study_id>
    <nct_id>NCT02337322</nct_id>
  </id_info>
  <brief_title>Immune Recovery in Advanced , ARV-naïve, HIV-1-infected Individuals Taking Dolutegravir or Ritonavir-boosted Darunavir</brief_title>
  <official_title>Immune Reconstitution in Severely Immunosuppressed Antiretroviral-naive HIV-1-Infected Patients (&lt;100 CD4+ T Cells/μL) Taking Antiretroviral Regimens Based on Dolutegravir or Ritonavir-boosted Darunavir (the Advanz-4 Trial).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Juan A. Arnaiz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are few randomized clinical trials in advanced HIV patients. This is a multicenter,
      randomized, open clinical trial, comparing 2 parallel groups, to compare the immunological
      reconstitution and the virological efficacy and safety of 2 different combinations of
      antiretroviral therapy given once a day (QD): abacavir plus lamivudine plus either
      dolutegravir, or darunavir-ritonavir during 96 weeks in advanced antiretroviral naïve HIV-1
      infected patients with less than 100 CD4+ T-cells/mm3. Primary endpoint is the median
      increase in CD4+ T-cell count at 48 weeks after starting HAART.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 31, 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median CD4 T cell count increase</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Acquired Immune Deficiency Syndrome Virus</condition>
  <arm_group>
    <arm_group_label>ABC+3TC+DTG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Abacavir+lamivudine+Dolutegravir, QD, Single tablet Regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABC+3TC+DRV/r</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Abacavir+lamivudine+ritonavir-boosted darunavir, QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dolutegravir</intervention_name>
    <arm_group_label>ABC+3TC+DTG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir/r</intervention_name>
    <arm_group_label>ABC+3TC+DRV/r</arm_group_label>
    <other_name>Ritonavir-boosted Darunavir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV patients &gt; 18 years old who provide signed and dated informed consent.

          2. Male and female.

          3. Chronic HIV infection.

          4. Antiretroviral naïve.

          5. Confirmed CD4+ T cell count below 100 cells/mm3

          6. HLA B5701 negative patients.

        Exclusion Criteria:

          1. Active opportunistic infections requiring parenteral treatment

          2. Patients with cryptococcal meningitis treated with voriconazole

          3. AIDS-defining cancers needing chemotherapy.

          4. Female patients pregnant or breastfeeding.

          5. Patients with documented history of allergy to sulfonamides.

          6. Any contraindications to study drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jose Miro, MD, PhD</last_name>
    <phone>+34932775586</phone>
    <email>jmmiro@ub.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Clinic of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <state>BCN</state>
        <zip>08013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Miro, PhD</last_name>
      <phone>+34932275586</phone>
      <email>jmmiro@ub.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2015</study_first_submitted>
  <study_first_submitted_qc>January 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2015</study_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Juan A. Arnaiz</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Acquired Immune Deficiency Syndrome Virus</keyword>
  <keyword>HIV</keyword>
  <keyword>HIV-1</keyword>
  <keyword>Antiretroviral treatment</keyword>
  <keyword>HIV Advanced Disease</keyword>
  <keyword>AIDS</keyword>
  <keyword>Dolutegravir</keyword>
  <keyword>Darunavir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Dolutegravir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

